Lentigen Receives SBIR Grant For Hepatitis C Vaccine

Lentigen has received a National Institutes of Health (NIH) small business innovation research (SBIR) grant for a program on ‘A Novel Method of Generating Hepatitis C virus (HCV) like particles using Lentivirus’. In this program, Lentigen will collaborate with Epixis SA (Paris, France).

Epixis SA has previously designed rVLPs pseudotyped with one or both of the HCV envelope proteins E1 and E2. Mice primed with a recombinant viral vector expressing E1 and E2 can mount unprecedented neutralizing humoral immune responses upon boosting with such pseudotyped rVLPs. Before reaching the clinic, their large scale production calls for a new efficient and safe system.

The company claims that the aim of this grant is the construction of a lentiviral vector expressing HCV rVLPs, and validation of its use for high titer production of HCV-rVLPs from human cells. This uses a similar approach to that being used in the development of a pandemic influenza VLP vaccine at Lentigen, supported by PATH.

Boro Dropulic, president and chief scientific officer of Lentigen, said: “The collaboration represents the integration of two important technologies to generate highly immunogenic HepC VLPs. The project is consistent with our strategy of applying Lentigen’s technology in diseases of high unmet therapeutic need.”

Reportedly, the Hepatitis C virus is the most common blood-borne virus and HCV infection represents a major public health concern approximately 3% of the world’s population (200 million people) is chronically infected. Causing fibrosis and cirrhosis of the liver and eventually hepatocellular carcinoma, it is the leading cause of liver transplantation in the US. No vaccine is currently available, said the company.